106 related articles for article (PubMed ID: 11755954)
1. Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod.
Dempfle CE; Alesci S; Kucher K; Müller-Peltzer H; Rübsamen K; Borggrefe M
Thromb Res; 2001 Dec; 104(6):433-8. PubMed ID: 11755954
[TBL] [Abstract][Full Text] [Related]
2. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
Dempfle CE; Argiriou S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
Blood; 2000 Oct; 96(8):2793-802. PubMed ID: 11023513
[TBL] [Abstract][Full Text] [Related]
3. Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity.
Dempfle CE; Argiriou S; Alesci S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
Ann N Y Acad Sci; 2001; 936():210-4. PubMed ID: 11460476
[TBL] [Abstract][Full Text] [Related]
4. Role of plasminogen activator inhibitor-1 in promoting fibrin deposition in rabbits infused with ancrod or thrombin.
Krishnamurti C; Bolan C; Colleton CA; Reilly TM; Alving BM
Blood; 1993 Dec; 82(12):3631-6. PubMed ID: 8260701
[TBL] [Abstract][Full Text] [Related]
5. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
[TBL] [Abstract][Full Text] [Related]
6. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits.
Krishnamurti C; Barr CF; Hassett MA; Young GD; Alving BM
Blood; 1987 Mar; 69(3):798-803. PubMed ID: 3101764
[TBL] [Abstract][Full Text] [Related]
8. Ancrod enhances the thrombolytic effect of streptokinase and urokinase.
Cercek B; Lew AS; Hod H; Yano J; Lewis B; Reddy KN; Ganz W
Thromb Res; 1987 Aug; 47(4):417-26. PubMed ID: 3660351
[TBL] [Abstract][Full Text] [Related]
9. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man.
Bell WR; Shapiro SS; Martinez J; Nossel HL
J Lab Clin Med; 1978 Apr; 91(4):592-604. PubMed ID: 641385
[TBL] [Abstract][Full Text] [Related]
10. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE
J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465
[TBL] [Abstract][Full Text] [Related]
11. Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis.
Nielsen VG
J Thromb Thrombolysis; 2016 Aug; 42(2):288-93. PubMed ID: 26905070
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
[TBL] [Abstract][Full Text] [Related]
13. Defibrinogenating enzymes.
Bell WR
Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
[TBL] [Abstract][Full Text] [Related]
14. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
15. The effect of fibrinolytic enzyme FIIa from Agkistrodon acutus venom on disseminated intravascular coagulation in rabbits.
Lin X; Liang XX; Chen JS; Chen Q; Qiu PX; Yan GM
Transl Res; 2007 Nov; 150(5):295-302. PubMed ID: 17964518
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
Pizzo SV; Schwartz ML; Hill RL; McKee PA
J Clin Invest; 1972 Nov; 51(11):2841-50. PubMed ID: 4263497
[TBL] [Abstract][Full Text] [Related]
17. Ancrod and fibrin formation: perspectives on mechanisms of action.
Liu S; Marder VJ; Levy DE; Wang SJ; Yang F; Paganini-Hill A; Fisher MJ
Stroke; 2011 Nov; 42(11):3277-80. PubMed ID: 21868728
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
Kruithof EK; Schleuning WD
Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
[TBL] [Abstract][Full Text] [Related]
19. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition.
Pinsky DJ; Liao H; Lawson CA; Yan SF; Chen J; Carmeliet P; Loskutoff DJ; Stern DM
J Clin Invest; 1998 Sep; 102(5):919-28. PubMed ID: 9727060
[TBL] [Abstract][Full Text] [Related]
20. The cleavage and inactivation of plasminogen activator inhibitor type 1 and alpha2-antiplasmin by reptilase, a thrombin-like venom enzyme.
Urano T; Ihara H; Takada Y; Fujie M; Takada A
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):145-53. PubMed ID: 10759007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
